Original Article

You have full text access to this OnlineOpen article

Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk†

  1. David A. Ralph PhD1,
  2. Lue Ping Zhao PhD2,
  3. Christopher E. Aston PhD3,
  4. Sharmila Manjeshwar PhD1,
  5. Thomas W. Pugh MS1,
  6. Daniele C. DeFreese MS1,
  7. Bobby A. Gramling MS1,
  8. Craig D. Shimasaki PhD1,
  9. Eldon R. Jupe PhD1,3,‡,*

Article first published online: 13 APR 2007

DOI: 10.1002/cncr.22634

Issue

Cancer

Cancer

Volume 109, Issue 10, pages 1940–1948, 15 May 2007

Additional Information

How to Cite

Ralph, D. A., Zhao, L. P., Aston, C. E., Manjeshwar, S., Pugh, T. W., DeFreese, D. C., Gramling, B. A., Shimasaki, C. D. and Jupe, E. R. (2007), Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer, 109: 1940–1948. doi: 10.1002/cncr.22634

Author Information

  1. 1

    InterGenetics Incorporated, Oklahoma City, Oklahoma

  2. 2

    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington

  3. 3

    General Clinical Research Center and Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  1. ‡

    Fax: (405) 271-1725

*InterGenetics Incorporated, 655 Research Parkway, Suite 300, Oklahoma City, OK 73104

  1. †

    All authors are either employees or consultants of InterGenetics Incorporated

Publication History

  1. Issue published online: 25 APR 2007
  2. Article first published online: 13 APR 2007
  3. Manuscript Accepted: 12 FEB 2007
  4. Manuscript Revised: 28 JAN 2007
  5. Manuscript Received: 27 OCT 2006

Funded by

  • U.S. Army Breast Cancer Research Program. Grant Number: DAMD17-01-1-0358
  • American Cancer Society. Grant Number: RPG-97-167-01-MGO
  • Oklahoma Center for the Advancement of Science and Technology. Grant Numbers: AR05.1025, AR02.2032, AR99.2-007, AR01.1-050
  • National Institutes of Health
  • National Center for Research Resources
  • General Clinical Research Center. Grant Number: M01RR-14467
  • Presbyterian Health Foundation
  • Oklahoma Life Sciences Fund
  • Swisher Family Trust

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (173K)

REFERENCES

  • 1
    Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol. 2005; 34: 405–412.
  • 2
    Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 1996; 17: 47–67.
  • 3
    Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002; 7: 3–15.
  • 4
    Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998; 279: 915–921.
  • 5
    Malone KE, Dailing JR, Neal C, et al. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA. 1998; 279: 922–929.
  • 6
    Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002; 31: 33–36.
  • 7
    Ponder BA, Antoniou A, Dunning A, Easton DF, Pharoah PD. Polygenic inherited predisposition to breast cancer. Cold Spring Harb Symp Quant Biol. 2005; 70: 35–41.
  • 8
    Dunning AM, Healey CS, Pharoah PD, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999; 8: 843–854.
  • 9
    de Jong MM, Nolte IM, te Meerman GJ, et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet. 2002; 39: 225–242.
  • 10
    Kristensen VN, Borresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res. 2000; 462: 323–333.
  • 11
    Thompson PA, Ambrosone C. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr. 2000; 27: 125–134.
  • 12
    Stravraky K, Emmons S. Breast cancer in premenopausal and postmenopausal women. J Natl Cancer Inst. 1974; 53: 644–654.
  • 13
    Paffenbarger RSJr, Kampert JB, Chang H-G. Characteristics that predict risk of breast cancer before and after the menopause. Am J Epidemiol. 1980; 112: 258–268.
  • 14
    Kampert JB, Whittemore AS, Paffenbarger RSJr. Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. Am J Epidemiol. 1988; 128: 962–979.
  • 15
    Clavel-Chapelon F, E3N-EPIC Group. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer. 2002; 86: 723–727.
  • 16
    Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998; 90: 1292–1299.
  • 17
    Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2005; 97: 755–765.
  • 18
    Thompson PA, Shields PG, Freudenheim JL, et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res. 1998; 58: 2107–2110.
  • 19
    Wedren S, Rudqvist TR, Granath F, et al. Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis. 2003; 24: 681–687.
  • 20
    Zhu Y, Brown HN, Zhang Y, Holford TR, Zheng T. Genotypes and halotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status. Breast Cancer Res. 2005; 7: R745–R752.
  • 21
    Bergman-Jungestrom M, Gentile M, Lundin AC, Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer. 1999; 84: 350–353.
    Direct Link:
  • 22
    Spurdle AB, Hopper JL, Dite GS, et al. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst. 2000; 92: 1674–1681.
  • 23
    Aston CE, Ralph DA, Lalo DP, et al. Oligogenic combinations associated with breast cancer risk. Hum Genet. 2005; 116: 208–221.
  • 24
    Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996; 6: 243–250.
  • 25
    Lavigne JA, Helzlsouer KJ, Huang HY, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res. 1997; 57: 5493–5497.
  • 26
    Connell JM, Fraser R, MacKenzie SM, et al. The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation. Mol Cell Endocrinol. 2004; 217: 243–247.
  • 27
    Barbato A, Russo P, Siani A, et al. Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population. J Hypertens. 2004; 22: 1895–1901.
  • 28
    Listgarten J, Damaraju S, Poulin B, et al. Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res. 2004; 10: 2725–3727.
  • 29
    Kristensen VN, Harada N, Yoshimura N, et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 2000; 19: 1329–1333.
  • 30
    Agoulnik IU, Tong XW, Fischer DC, et al. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab. 2004; 89: 6430–6347.
  • 31
    De Vivo I, Hankinson SE, Colditz GA, Hunter DJ. The progesterone receptor Val660Leu polymorphism and breast cancer risk. Breast Cancer Res. 2004; 6: R636–R639.
  • 32
    Rosenblum JS, Gilula NB, Lerner RA. On signal sequence polymorphisms and diseases of distribution. Proc Nat Acad Sci USA. 1996; 93: 4471–4473.
  • 33
    Mitrunen K, Sillanpaa P, Kataja V, Eskelinen M, et al. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis. 2001; 22: 827–829.
  • 34
    Strassburg CP, Vogel A, Kneip S, Tukey RH, Manns MP. Polymorphisms of the human UDP-glucuronosyltransferase (UGT)1A7 gene in colorectal cancer. Gut. 2002; 50: 851–856.
  • 35
    Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst. 2001; 93: 1411–1418.
  • 36
    Van der Logt EM, Bergevoet SM, Roelofs HM, et al. Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis. 2004; 25: 2407–2415.
  • 37
    Hartl DL, Clark AG. Principles of Population Genetics. Sunderland, Mass: Sinauer Associates, Inc.; 1997.
  • 38
    Everitt BS. The Analysis of Contingency Tables. ed. 2. London: Chapman and Hall; 1986.
  • 39
    Breslow N E, Day NE. Statistical Methods in Cancer Research. Lyon: International Agency for Research on Cancer 1980.
  • 40
    Nichols HB, Trentham-Dietz A, Hampton JM, et al. From menarche to menopause: trends among US women born from 1912 to 1969. Am J Epidemiol. 2006; 164: 1003–1011.
  • 41
    Overlie I, Moen MH, Morkrid L, Skjaeraasen JS, Holte A. The endocrine transition around menopause—a five years prospective study with profiles of gonadotropins, estrogens, androgens and SHBG among healthy women. Acta Obstet Gynecol Scand. 1999; 78: 642–647.
    Direct Link:
  • 42
    Tworoger S, Missmer S, Eliassen A, et al. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev. 2006; 15: 967–971.
  • 43
    Missmer S, Eliassen A, Barbieri R, Hankinson S. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004; 96: 1856–1865.
  • 44
    Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006; 98: 1406–1415.
  • 45
    Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94: 606–616.
  • 46
    Gail M, Brinton L, Byar D, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81: 1879–1886.
  • 47
    Anderson W, Matsuno R, Sherman M, et al. Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes Control. 2007 Jan 9; [Epub ahead of print].
  • 48
    Largent J, Ziogas A, Anton-Culver H. Effect of reproductive factors on stage, grade and hormone receptor status in early-onset breast cancer. Breast Cancer Res. 2005; 7: R541–R554.
  • 49
    Huang Z, Hankinson S, Colditz G, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997; 278: 1407–1411.
  • 50
    Lahmann P, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2004; 111: 762–71.
    Direct Link:
  • 51
    Ranade K, Wu KD, Risch N, et al. Genetic variation in aldosterone synthase predicts plasma glucose levels. Proc Natl Acad Sci USA. 2001; 98: 13219–13224.
  • 52
    Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care. 2003; 26: 1752–1758.
  • 53
    Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat. 2006; 98: 349–356.
  • 54
    Ogura K, Ishikawa Y, Kaku T, et al. A. Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol. 2006; 71: 1358–1369.
  • 55
    Feigelson HS, Rodriguez C, Jacobs EJ, Diver WR, Thun MJ, Calle EE. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13: 1084–1085.
  • 56
    Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet. 2001; 29: 306–309.
View Full Article (HTML) Get PDF (173K)